Senhwa Biosciences, Inc. (TPEx: 6492, “Senhwa”), a clinical-stage biopharmaceutical company developing first-in-class therapies for difficult-to-treat cancers, today announced a significant milestone in the global immuno-oncology landscape. In collaboration with the US National Cancer Institute (NCI), part of the US National Institutes of Health, the NCI sponsored clinical trial 10716 has successfully enrolled and dosed the first patient in an international clinical trial evaluating its innovative anticancer candidate, Pidnarulex (CX-5461), in combination with Cemiplimab (Libtayo®)—a marketed PD-1 immune checkpoint inhibitor from global pharmaceutical leaders Sanofi and Regeneron Pharmaceuticals.
This trial targets treatment-resistant microsatellite-stable colorectal cancer (MSS CRC) and is sponsored by the NCI, part of National Institutes of Health, under a Cooperative Research and Development Agreement between NCI and Senhwa, and led and conducted by the NCI's Experimental Therapeutics Clinical Trials Network (ETCTN). The multinational collaboration further underscores the drug’s novel mechanism and its promising potential as a strategic combination partner in next-generation immunotherapy—earning increasing attention from major global pharma.
Dr. Pin Yen Huang, Chief Medical Officer of Senhwa, stated:
“This trial represents a new chapter in global cancer treatment. By combining CX-5461 with a PD-1 inhibitor, we aim to provide a much-needed therapeutic option for patients who have not benefited from existing immunotherapies, while showcasing the impact of Taiwan-developed innovative medicines on the world stage.”
MSS CRC accounts for approximately 95% of all colorectal cancer cases, yet effective treatment options remain limited. Incidence among younger adults continues to rise, and patients often experience poor responses to immunotherapy, drug resistance, and high treatment costs—further complicated by the lack of reliable biomarkers for clinical decision-making.The CX-5461 and Cemiplimab combination trial, with its precision-driven design, aims to overcome these barriers and introduce a new therapeutic avenue that may prolong survival and improve quality of life.
In recent years, immune checkpoint inhibitors have transformed cancer care, yet response rates in most solid tumors remain at only 20–30%. CX-5461 is the world’s first small-molecule agent capable of modulating the tumor immune microenvironment. Its mechanism enhances the infiltration of dendritic cells, natural killer cells, and cytotoxic T cells into the tumor core—strengthening antitumor immunity while inducing durable immune memory to help eliminate tumors and reduce recurrence.
Notably, prior clinical studies of CX-5461 have not shown bone marrow suppression, allowing safe combination with PD-1 inhibitors and providing a significant advantage over conventional chemotherapeutics. These attributes position CX-5461 as a potential game-changer in improving immunotherapy response rates and expanding the therapeutic reach of existing checkpoint inhibitors.
The global cancer immunotherapy market is entering a high-growth phase. According to Coherent Market Insights, the market is projected to exceed USD 150 billion by 2025, with continued double-digit compound annual growth expected to push the sector beyond USD 300 billion by 2035. Combination immunotherapies remain a major priority for multinational pharmaceutical companies, attracting the largest strategic investments worldwide.
Amid this trend, innovative small-molecule therapies with first-in-class mechanisms—particularly those capable of enhancing immune responses and reshaping the tumor microenvironment—have become top licensing and acquisition targets for global pharma. With its differentiated mechanism and demonstrated potential in immunotherapy enhancement, CX-5461 is strongly positioned as a valuable strategic asset, poised to deliver meaningful advances for patients while creating long-term value for partners and investors alike.